|Bid||28.89 x 800|
|Ask||34.63 x 800|
|Day's Range||34.39 - 34.73|
|52 Week Range||32.33 - 41.55|
|Beta (3Y Monthly)||0.68|
|PE Ratio (TTM)||41.18|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.00|
Frankfurt Prime Standard: QIA) today announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis. The QIAstat-Dx Gastrointestinal Panel delivered high performance compared to other, existing multiplex tests in this study which evaluated 385 patient samples at university hospital laboratories across Europe. Multiple pathogens were identified in nearly one-third of the patient samples that tested positive.
Rome, L6, based Investment company Bank of Italy (Current Portfolio) buys Qiagen NV, sells Ferrari NV during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Bank of Italy. Continue reading...
Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN N.V. today announced results of operations for the second quarter of 2019, achieving the outlook set for net sales growth and adjusted earnings per share at constant exchange rates .
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN N.V. plans as previously announced to release its report on results for the second quarter and first half of 2019 on Tuesday, July 30 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .
After QIAGEN N.V.'s (NYSE:QGEN) earnings announcement in March 2019, analysts seem fairly confident, as a 19% increase...
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
Frankfurt Prime Standard: QIA) today announced an agreement for McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation , a global leader in healthcare supply chain management solutions, to serve as the exclusive distributor of QIAGEN’s QIAstat-Dx syndromic testing solution in the “acute” market segment of U.S. hospitals with 200 beds or less and in other select segments. The agreement also makes McKesson a non-exclusive distributor for future expansion of QIAstat-Dx into the non-acute retail clinics located in U.S. retail pharmacies.
How do we determine whether Qiagen NV (NYSE:QGEN) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]